Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
v-ral simian leukemia viral oncogene homolog A pseudogene" (ENSG00000231525) is classified as a **pseudogene**, meaning it is a genomic DNA sequence that resembles a functional gene (specifically the RALA oncogene) but lacks the ability to produce a functional protein. Pseudogenes typically arise from duplication or retrotransposition events and carry mutations (such as frameshifts or stop codons) that prevent their translation or expression as active proteins[1][2][3]. While most pseudogenes are considered transcriptionally inactive and functionless, some may be transcribed at low levels and can occasionally have regulatory roles at the RNA level, including acting as microRNA sponges or generating regulatory noncoding RNAs[5][6]. However, there is no evidence that this particular pseudogene has any functional or therapeutic relevance, nor is it considered a drug target[4]. Pseudogenes can complicate genetic studies and annotation but are not relevant to pharmacological intervention or biomarker discovery[3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on v-ral simian leukemia viral oncogene homolog A pseudogene.